Global Market AccessWebinars & PodcastsPharmaGlobal Whispers

Market access for digital therapies and digital medicines

In the second episode of our Global Whispers webinar series, we explored market access for digital therapeutics. Clare Foy (Global Market Access Director – Mtech Access) spoke to Shefali Shah (Global VP, Market Value and Commercial Effectiveness – MindMaze) about the challenges and opportunities for digital therapies to gain market access and ultimately improve patient outcomes.

Listen to the podcast:

This episode is also available as a podcast. Listen below or search ‘Pharma Market Access Insights  – from Mtech Access’ on Spotify, Apple Podcasts or Google Podcasts.

Digital technologies offer exciting opportunities for the future of healthcare, with many patient pathways likely to be transformed by new innovations in the coming years. As digital therapies become more common place, how are companies navigating international healthcare markets to bring their treatments to patients?

In this webinar, Shefali Shah compares her experiences of launching digital therapeutics at MindMaze with her previous roles in Pharmaceutical market access with NovoNordisk, GSK and others. Clare and Shefali discuss the different routes to market for digital innovators and how this compares to the market access landscape for other treatments including medical devices, diagnostics and more traditional medicines.

In the webinar, Clare asks Shefali about:

  • The opportunities for digital technologies in neurology and how they may impact existing care pathways in the future
  • How the digital technology market differs from the pharmaceutical market
  • Regulatory and reimbursement challenges for digital technologies
  • Her experiences in launching digital technologies in markets such as the US and Germany
  • How digital technologies can be used to enhance and complement existing treatments/pathways of care
  • Lessons other digital health, medical device and pharmaceutical companies can learn from Shefali’s experiences

More about our speaker

Shefali Shah (Global VP, Market Value and Commercial Effectiveness at MindMaze)

Shefali is responsible for developing the global market access and reimbursement strategy at MindMaze. Founded in 2012, MindMaze is a global leader in brain technology. With over a decade of work at the intersection of neuroscience, biosensing, engineering, mixed reality and artificial intelligence, the company specialises in enhancing the recovery potential of patients with neurological diseases.

With 20 years of experience in Life Sciences, Shefali has been instrumental in launching several blockbuster products and growing in-market products for companies like Novo Nordisk, GSK, and others. Shefali brings a wide range of expertise in optimising commercial execution based on her experience in leading and aligning Medical, Market Access, Insights and Brand Teams.

Additionally, Shefali combines her passion for science and evidence-based data with her experience with ancient wisdom traditions like yoga and meditation to advance health and wellness. Shefali earned a BS in Electrical Engineering from Columbia University in the City of New York and an MBA from NYU Stern School of Business, and is a RYS Certified Yoga Instructor.

We were delighted to welcome Shefali to the Global Whispers webinar series.

The Global Whispers webinar series

This webinar is the second in our Global Whispers series. For over 2 years, Mtech Access have presented an industry-renowned NHS Whispers webinar series, where we interview experts from the UK healthcare system about the market landscape and the evolving challenges in the NHS. Following the success of this series, we are launching a new series looking at global market access challenges facing the Pharmaceutical and Medtech industries and offering insights into key launch markets.

In May, Michael Sassano (CEO – SOMAÍ Pharmaceuticals) joined us to share his global market access journey in cannabinoid pharmaceuticals. Following this webinar, in July we will be focusing on market access challenges in the DACH region.

Learn more about our expertise in:

Global Market Access

Leave a Reply